Clinical genomics: When whole genome sequencing is like a whole-body CT scan

Jason Y. Park, Larry J. Kricka, Peter Clark, Eric Londin, Paolo Fortina

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Although we have witnessed major improvements in genomic testing in the past 5 years, multiple challenges need to be solved before clinical genomic testing becomes routine (1 ). The clinical implementation of genomic testing parallels the challenges we have faced with other transformative technologies. For the past decade, the medical community has been discussing the impact on healthcare and society of direct-toconsumer marketed whole-body computed tomography (CT)8 scanning (2 ). The CT scan is a technology that uses X-rays to produce cross-sectional images of the human body. There are clinical scenarios in which the CT scan is invaluable: disease diagnosis, evaluation after trauma, and monitoring response to oncologic therapy. However, CT scan is also being marketed as a preventive diagnostic for healthy individuals (3 ). Genomics can parallel CT scanning in scenarios of (a) first line diagnostic testing, (b) last ditch diagnosis, and (c) inappropriate clinical use. Genomic testing implies the examination of the nucleic acid sequence of multiple, if not all, known genes. Broadly, this includes microarray tests that survey changes in single nucleotide polymorphisms (SNPs) and copy-number variation across the entire genome, sequencing the exome or whole genome by nextgeneration sequencing, and sequencing large panels of clinically significant genes. Genomic testing is currently moving from academic research practice to commercialization and direct-to-consumer marketing. Although genomic testing is not yet routine, DNA testing targeted to single genes, viruses, or bacteria is commonplace and performed in many clinical laboratories. The use of genetic information has evolved over the past decade from targeted single-gene tests to broader genomic tests that encompass thousands of genes. Numerous ethical, economic, and technological challenges need to be addressed before widespread adoption of clinical genomic testing. For example, a patient may not want to know their future risk of disease; a patient (and society) may not be able to afford genomic testing. In addition, genomic testing may not be appropriate for all diseases.

Original languageEnglish (US)
Pages (from-to)1390-1392
Number of pages3
JournalClinical Chemistry
Volume60
Issue number11
DOIs
StatePublished - Nov 1 2014

Fingerprint

Genomics
Tomography
Genes
Genome
Testing
Exome
Technology
Human Body
Nucleic Acids
Single Nucleotide Polymorphism
Economics
X-Rays
Nucleic acid sequences
Viruses
Bacteria
Delivery of Health Care
Clinical laboratories
Scanning
DNA
Wounds and Injuries

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical
  • Medicine(all)

Cite this

Clinical genomics : When whole genome sequencing is like a whole-body CT scan. / Park, Jason Y.; Kricka, Larry J.; Clark, Peter; Londin, Eric; Fortina, Paolo.

In: Clinical Chemistry, Vol. 60, No. 11, 01.11.2014, p. 1390-1392.

Research output: Contribution to journalArticle

Park, Jason Y. ; Kricka, Larry J. ; Clark, Peter ; Londin, Eric ; Fortina, Paolo. / Clinical genomics : When whole genome sequencing is like a whole-body CT scan. In: Clinical Chemistry. 2014 ; Vol. 60, No. 11. pp. 1390-1392.
@article{2be7d85cbc534caea4e9033b05cbf7a2,
title = "Clinical genomics: When whole genome sequencing is like a whole-body CT scan",
abstract = "Although we have witnessed major improvements in genomic testing in the past 5 years, multiple challenges need to be solved before clinical genomic testing becomes routine (1 ). The clinical implementation of genomic testing parallels the challenges we have faced with other transformative technologies. For the past decade, the medical community has been discussing the impact on healthcare and society of direct-toconsumer marketed whole-body computed tomography (CT)8 scanning (2 ). The CT scan is a technology that uses X-rays to produce cross-sectional images of the human body. There are clinical scenarios in which the CT scan is invaluable: disease diagnosis, evaluation after trauma, and monitoring response to oncologic therapy. However, CT scan is also being marketed as a preventive diagnostic for healthy individuals (3 ). Genomics can parallel CT scanning in scenarios of (a) first line diagnostic testing, (b) last ditch diagnosis, and (c) inappropriate clinical use. Genomic testing implies the examination of the nucleic acid sequence of multiple, if not all, known genes. Broadly, this includes microarray tests that survey changes in single nucleotide polymorphisms (SNPs) and copy-number variation across the entire genome, sequencing the exome or whole genome by nextgeneration sequencing, and sequencing large panels of clinically significant genes. Genomic testing is currently moving from academic research practice to commercialization and direct-to-consumer marketing. Although genomic testing is not yet routine, DNA testing targeted to single genes, viruses, or bacteria is commonplace and performed in many clinical laboratories. The use of genetic information has evolved over the past decade from targeted single-gene tests to broader genomic tests that encompass thousands of genes. Numerous ethical, economic, and technological challenges need to be addressed before widespread adoption of clinical genomic testing. For example, a patient may not want to know their future risk of disease; a patient (and society) may not be able to afford genomic testing. In addition, genomic testing may not be appropriate for all diseases.",
author = "Park, {Jason Y.} and Kricka, {Larry J.} and Peter Clark and Eric Londin and Paolo Fortina",
year = "2014",
month = "11",
day = "1",
doi = "10.1373/clinchem.2014.230276",
language = "English (US)",
volume = "60",
pages = "1390--1392",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "11",

}

TY - JOUR

T1 - Clinical genomics

T2 - When whole genome sequencing is like a whole-body CT scan

AU - Park, Jason Y.

AU - Kricka, Larry J.

AU - Clark, Peter

AU - Londin, Eric

AU - Fortina, Paolo

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Although we have witnessed major improvements in genomic testing in the past 5 years, multiple challenges need to be solved before clinical genomic testing becomes routine (1 ). The clinical implementation of genomic testing parallels the challenges we have faced with other transformative technologies. For the past decade, the medical community has been discussing the impact on healthcare and society of direct-toconsumer marketed whole-body computed tomography (CT)8 scanning (2 ). The CT scan is a technology that uses X-rays to produce cross-sectional images of the human body. There are clinical scenarios in which the CT scan is invaluable: disease diagnosis, evaluation after trauma, and monitoring response to oncologic therapy. However, CT scan is also being marketed as a preventive diagnostic for healthy individuals (3 ). Genomics can parallel CT scanning in scenarios of (a) first line diagnostic testing, (b) last ditch diagnosis, and (c) inappropriate clinical use. Genomic testing implies the examination of the nucleic acid sequence of multiple, if not all, known genes. Broadly, this includes microarray tests that survey changes in single nucleotide polymorphisms (SNPs) and copy-number variation across the entire genome, sequencing the exome or whole genome by nextgeneration sequencing, and sequencing large panels of clinically significant genes. Genomic testing is currently moving from academic research practice to commercialization and direct-to-consumer marketing. Although genomic testing is not yet routine, DNA testing targeted to single genes, viruses, or bacteria is commonplace and performed in many clinical laboratories. The use of genetic information has evolved over the past decade from targeted single-gene tests to broader genomic tests that encompass thousands of genes. Numerous ethical, economic, and technological challenges need to be addressed before widespread adoption of clinical genomic testing. For example, a patient may not want to know their future risk of disease; a patient (and society) may not be able to afford genomic testing. In addition, genomic testing may not be appropriate for all diseases.

AB - Although we have witnessed major improvements in genomic testing in the past 5 years, multiple challenges need to be solved before clinical genomic testing becomes routine (1 ). The clinical implementation of genomic testing parallels the challenges we have faced with other transformative technologies. For the past decade, the medical community has been discussing the impact on healthcare and society of direct-toconsumer marketed whole-body computed tomography (CT)8 scanning (2 ). The CT scan is a technology that uses X-rays to produce cross-sectional images of the human body. There are clinical scenarios in which the CT scan is invaluable: disease diagnosis, evaluation after trauma, and monitoring response to oncologic therapy. However, CT scan is also being marketed as a preventive diagnostic for healthy individuals (3 ). Genomics can parallel CT scanning in scenarios of (a) first line diagnostic testing, (b) last ditch diagnosis, and (c) inappropriate clinical use. Genomic testing implies the examination of the nucleic acid sequence of multiple, if not all, known genes. Broadly, this includes microarray tests that survey changes in single nucleotide polymorphisms (SNPs) and copy-number variation across the entire genome, sequencing the exome or whole genome by nextgeneration sequencing, and sequencing large panels of clinically significant genes. Genomic testing is currently moving from academic research practice to commercialization and direct-to-consumer marketing. Although genomic testing is not yet routine, DNA testing targeted to single genes, viruses, or bacteria is commonplace and performed in many clinical laboratories. The use of genetic information has evolved over the past decade from targeted single-gene tests to broader genomic tests that encompass thousands of genes. Numerous ethical, economic, and technological challenges need to be addressed before widespread adoption of clinical genomic testing. For example, a patient may not want to know their future risk of disease; a patient (and society) may not be able to afford genomic testing. In addition, genomic testing may not be appropriate for all diseases.

UR - http://www.scopus.com/inward/record.url?scp=84907490642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907490642&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2014.230276

DO - 10.1373/clinchem.2014.230276

M3 - Article

C2 - 25114273

AN - SCOPUS:84907490642

VL - 60

SP - 1390

EP - 1392

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 11

ER -